🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Board Director Changes SEC Filings — May 27, 2026

The 32 filings from May 27, 2026, reveal a bifurcated market where strong operational performance at Agilent and Braze contrasts with consumer-facing weakness at Bath & Body Works. Board room changes are dominated by routine governance (annual meetings, equity plan approvals) and leadership transitions, with notable CEO appointments at Immunic (pre-commercial biotech) and Kemper (insurance turnaround). A key theme is the high level of shareholder dissent on equity dilution, with Xerox (25.5% against) and Dermata (low 'For' votes) flagging governance risk. Insider activity is limited, but the CFO departures at Bath & Body Works and Rollins introduce transition risk. Period-over-period data shows a mixed picture: Agilent's 10% revenue growth and margin expansion contrast with Bath & Body Works' 3% sales decline and 280 bps gross margin compression. The most critical developments are the high-stakes catalyst at Immunic (Phase 3 data readout) and the significant management overhaul at Braze, which accompanies strong revenue growth but margin pressure.

32 high priority 32 total filings
· daily

US Merger & Acquisition SEC Filings — May 27, 2026

The US M&A landscape on May 27, 2026, reveals a market bifurcated between high-conviction, high-value transactions and distressed SPACs facing existential regulatory and financial pressures. The most significant development is the $3.8 billion de-SPAC merger between ProLogium and TDAC, a high-risk/high-reward play in next-gen battery technology, while the completed $3.5 billion take-private of Veris Residential demonstrates strong private equity appetite for real assets. However, a troubling pattern emerges among SPACs: three entities (Charlton Aria, ASPAC III, Flag Ship) have received Nasdaq deficiency notices for late filings or low equity, signaling systemic operational and compliance failures. The Live Oak-Teamshares deal introduces significant governance risk by proceeding without a fairness opinion or redemption threshold. Capital markets remain open for new SPAC IPOs, with Oceanhawk and Amanat raising a combined $235 million, indicating continued sponsor appetite despite the sector's headwinds. The overall sentiment is mixed, with a clear divergence between well-capitalized, execution-focused deals and a cohort of struggling blank-check companies.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 27, 2026

The overnight filing cycle reveals a market bifurcated between robust operational execution in select industrials and consumer discretionary names versus acute financial distress in micro-cap and pre-revenue companies. Dycom Industries and Dick's Sporting Goods posted standout revenue growth of 56% and 63% YoY respectively, driven by acquisitions and organic share gains, though margin compression from deal costs is a clear headwind. Conversely, Trillion Energy, Hi-Great Group, and GridAI Technologies reported widening losses and deteriorating cash positions, signaling severe liquidity risks. The healthcare sector is a key source of alpha, with Apogee Therapeutics announcing positive Phase 2 data and a $1.3B non-dilutive financing deal, while Immunic appointed a new CEO ahead of a pivotal Phase 3 readout. Capital allocation patterns are mixed: Movado raised its dividend by 14%, while Callan JMB and Data Storage Corp authorized dilutive ATM offerings. A major M&A theme is emerging with GameStop's non-binding $125/share bid for eBay and the ProLogium SPAC merger at a $3.8B valuation, both carrying significant execution risk. Insider activity is sparse in this batch, but the high number of restatements (Goldenwell Biotech) and going-concern warnings (NextTrip) demand caution. Overall, the data suggests a 'barbell' market where strong operators are rewarded and weak balance sheets are punished, with healthcare catalysts and M&A providing the most actionable near-term opportunities.

20 high priority 30 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 26, 2026

During the single-day period of May 26, 2026, the FDA issued 7 approvals, all classified as 'Other' (generic/biosimilar entries). There were zero NMEs, zero biosimilars (in the traditional biologic sense), and zero label expansions, resulting in a low-catalyst session for biotech investors. The dominant theme is generic erosion of established branded franchises, with notable entries for EMPAGLIFLOZIN (Aurobindo, targeting Jardiance) and SITAGLIPTIN/METFORMIN (Mankind Pharma, targeting Janumet). The only bullish signal came from Galderma’s label expansion for ADAPALENE/BENZOYL PEROXIDE (DIFFERIN/EPIDUO franchise), though materiality is moderate. Key risk: the wave of small-molecule generics approved here increases IRA exposure risk for originators, as these drugs face Medicare price negotiation at year 9 post-approval.

7 total filings
· daily

Big Pharma Approvals — May 26, 2026

The May 26, 2026 approval stream is exceptionally narrow, comprising a single label expansion for AbbVie’s linaclotide (LINZESS). There were no NME, biosimilar, or other label expansion approvals during this period, resulting in no dominant therapeutic area theme. The highest-conviction signal is the bullish label expansion for linaclotide, which extends AbbVie’s GI franchise but carries only moderate commercial materiality given the drug’s established market presence. The key watch item is the lack of NME or biosimilar approvals, which provides no fresh pipeline or competitive disruption signals for the sector.

1 total filings
· daily

New Drug Approvals (Original) — May 26, 2026

This digest covers 7 FDA approvals from May 20-22, 2026, all classified as 'Other' (non-NME, non-biosimilar, non-label-expansion) with a mix of one label expansion and six generic/biosimilar-type approvals. The dominant theme is generic/biosimilar competition across established therapeutic categories—dermatology, CNS, diabetes, and thyroid—with no novel molecular entities or breakthrough designations. The highest-conviction signal is the label expansion for ADAPALENE, BENZOYL PEROXIDE (DIFFERIN EPIDUO ACNE GEL) by GALDERMA LABORATORIES, L.P, which is bullish for Galderma's dermatology franchise. A key risk is the lack of NME approvals, signaling a quiet period for innovative pipeline catalysts, while the cluster of generic approvals for high-volume drugs like SITAGLIPTIN, METFORMIN HYDROCHLORIDE and EMPAGLIFLOZIN may pressure originator revenues for Merck and Boehringer Ingelheim/Eli Lilly, respectively.

7 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 26, 2026

The 9 filings in this S&P 500 Technology stream reveal a bifurcated landscape: while routine corporate governance events (annual meetings, auditor ratifications) at smaller financial firms like NorthEast Community Bancorp and First Northern Community Bancorp show stable shareholder support, the most material and actionable intelligence centers on a major strategic pivot at Cogent Communications and a deep financial restructuring at Veradigm. Cogent's $225M sale of 10 data centers to I Squared Capital signals a clear shift toward a pure-play optical IP network model, a high-materiality event (7/10) that could unlock value but lacks disclosed financial impact. Veradigm's long-awaited 10-K filings expose a severe deterioration: revenue declined 5.1% YoY to $594M, net income swung from +$49M to -$292M, and adjusted EBITDA fell 28.5% to $94M, with preliminary 2025 guidance suggesting a further 1-2% decline. The Genco Shipping & Trading proxy fight with Diana Shipping adds a high-stakes M&A catalyst (materiality 9/10), where Genco argues Diana's $23.50 offer is inadequate but acknowledges its stock has only traded above that level 40% of the time in 2026, creating a binary event. Across the stream, period-over-period comparisons highlight margin compression and revenue declines at Veradigm, while Cogent's divestiture and Genco's defense provide contrasting opportunities. Insider activity is notably absent from these filings, but forward-looking data (Veradigm's guidance, Cogent's closing date, Genco's tender timeline) builds a catalyst calendar for the next 30-60 days.

3 high priority 6 medium 9 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 26, 2026

The May 26, 2026 filing batch reveals a market bifurcated between aggressive corporate action and operational distress. The most material themes are a hostile takeover battle in dry bulk shipping (Genco vs. Diana), a major SPAC merger in quantum computing (Axiom/Terra Quantum), and a significant financial reporting crisis at Veradigm, which finally filed long-delayed 10-Ks showing a sharp 5.1% revenue decline and a swing to a $292M net loss. Period-over-period data highlights a clear trend of margin compression and revenue deceleration in the healthcare IT and shipping sectors. Capital allocation is mixed, with Genco defending its dividend against a low-ball bid, while NIQ Global receives strong shareholder backing for a buyback authorization. Insider activity is notably absent in most filings, but the Veradigm consulting agreement signals a desperate need for financial controls. The overarching theme is that while some companies are pursuing transformative M&A (Axiom, Cogent), others are fighting for survival or facing significant governance headwinds, creating a high-dispersion environment for active investors.

7 high priority 9 medium 16 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 26, 2026

The 50 filings for S&P 500 Financials on May 26, 2026 reveal a sector bifurcated between capital-rich institutions deploying leverage and smaller entities facing existential liquidity pressures. Key period-over-period trends include margin compression across industrials and specialty finance, with CSW Industrials experiencing a 490 bps operating margin decline despite 23% revenue growth, while Ares Capital and Ares Strategic Income Fund secured $9.6 billion in combined credit facilities, signaling robust institutional access to capital. The most critical developments include GameStop's unsolicited $125/share bid for eBay, Cumberland Pharmaceuticals' $100M asset sale to Apotex, and Northern Oil & Gas's $259M entry into Canadian Duvernay Shale, all representing transformative M&A. Portfolio-level patterns show a clear divergence: large-cap financials and BDCs are expanding leverage and returning capital via buybacks and dividends, while micro-cap firms like TransCode Therapeutics and Nuvve Holding face Nasdaq delisting risks due to equity deficiencies and filing failures.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 26, 2026

The 50 filings for the S&P 500 Consumer Staples sector reveal a sector in transition, with significant divergence between core staples and adjacent industries. While the sector shows limited direct insider trading activity, a major development is the loss of a >10% revenue customer at Verra Mobility, which has triggered a full-year guidance cut, creating a high-conviction negative signal. A key positive is McCormick & Co's appointment of a former AstraZeneca digital chief, signaling a strategic push into digital transformation. Capital allocation patterns are mixed, with a notable $900M debt offering for a transformative acquisition at Worthington Steel and a $50M preferred share placement at Angel Oak Financial. The most critical portfolio-level trend is the prevalence of 'mixed' sentiment in 8 filings, indicating a sector grappling with cost inflation, capacity expansion, and strategic pivots. Forward-looking data highlights a catalyst-rich period with several shareholder meetings and regulatory deadlines in late May and June 2026, demanding close monitoring for governance and strategic shifts.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 26, 2026

The 50 filings from the S&P 500 Industrials stream reveal a sector in flux, with a pronounced divergence between established industrial firms executing strategic divestitures and a wave of high-risk, high-reward SPAC mergers in quantum and modular housing. Period-over-period data from a few key filings shows severe financial distress, with Destination XL Group's sales falling 10% short of targets and net income swinging from a $3.1M profit to a $35.9M loss, while OPGEN's revenue surged 481% YoY driven by a pivot to listing sponsorship services. The most critical developments include multiple unsolicited takeover bids (Genco Shipping, Destination XL) and SPAC combinations (Bleichroeder/Pasqal, Axiom/Terra Quantum, FG Merger/Boxabl), signaling a wave of consolidation and speculative capital formation. Insider activity is sparse, but the lack of insider buying amidst these transactions is a notable concern. Capital allocation trends show a mix of dividend declarations (TriCo Bancshares), debt refinancing (BlackRock Monticello, Urban Outfitters), and a significant $100M asset sale by Cumberland Pharmaceuticals. Portfolio-level patterns highlight a 'flight to liquidity' as companies with weak balance sheets face existential risks, while those with strong cash positions pursue transformative M&A.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 26, 2026

The four filings in the S&P 500 Energy stream for May 26, 2026, reveal a sector in transition, with corporate governance and structural changes dominating over operational updates. The most critical development is ExxonMobil's push to redomicile from Delaware to Texas, a move with significant governance and legal implications that will be voted on imminently. APA Corp's annual meeting showed strong shareholder support for management, though notable dissent on executive compensation (14% against) signals a need for closer scrutiny of pay practices. The inclusion of two non-energy entities—a SPAC (Hall Chadwick) and a royalty company (XOMA Royalty)—highlights the stream's broadening scope, with XOMA's high-stakes merger with Ligand Pharmaceuticals representing a material 9/10 event. Period-over-period data from Hall Chadwick shows a 26.6% decline in cash reserves (from $631K to $463K) as it burns capital in its pre-business combination phase, while interest income from its trust account grew to $1.84M in Q1 2026. Overall, the sector is exhibiting a mix of defensive governance moves and high-risk M&A catalysts, with no direct operational or insider trading signals from the energy majors in this batch.

3 high priority 1 medium 4 total filings
· daily

US Material Events SEC 8-K Filings — May 26, 2026

The 50 filings reveal a mixed landscape dominated by capital structure actions (debt offerings, credit facility amendments, equity raises) and corporate events (M&A, Chapter 11, executive changes). Notable themes include a surge in debt capital market activity (Ares Capital, Starwood Property, Encore Capital) signaling strong institutional appetite for yield, while several companies (Trinseo, World Acceptance) show financial distress. The energy sector sees a strategic Canadian entry by Northern Oil & Gas, while tech/biotech companies (Assembly Biosciences, Editas Medicine) pursue dilutive financings. Insider activity is limited, but executive departures (Cartesian CMO, SS Innovations CFO) raise governance concerns. Period-over-period comparisons are sparse, but covenant modifications and repeated note amendments (Odyssey Health) indicate liquidity pressures. Overall, the digest highlights a bifurcated market: well-capitalized firms accessing debt markets cheaply, while weaker players rely on dilutive equity or face restructuring.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 26, 2026

The 50 filings reveal a mixed landscape for Dow 30 constituents, with notable revenue growth at ARM Holdings (+23% YoY) and OPGEN (+481% YoY), offset by sharp declines at Veradigm (-5% YoY) and Barnwell Industries (-29% YoY). Insider activity is sparse but includes a significant CEO departure at SS Innovations and a CFO resignation at Sculptor. Forward-looking guidance was revised downward at Verra Mobility due to a major customer loss, while Ryan Specialty boosted its buyback authorization by $300M. Capital allocation trends show steady dividends at TriCo Bancshares and increased buyback capacity at Ryan Specialty. M&A activity includes Cogent's $225M data center sale and the Terra Quantum SPAC merger. Sentiment is generally neutral, with pockets of positive (Palomar board appointment, D-Wave funding) and negative (Verra Mobility, Nuvve delisting risk). Key themes include margin compression (ARM, Veradigm), revenue concentration risk (Verra Mobility, SOLV Energy), and governance concerns (Viking Therapeutics, Veritone).

20 high priority 30 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 26, 2026

The May 26, 2026 filings reveal a market dominated by capital markets activity (IPOs, debt issuances, buybacks) and regulatory milestones, with several high-conviction signals emerging. Key themes include a wave of SPAC and IPO filings (Quantinuum, Applied Aerospace, INNIO) with price ranges indicating strong demand, alongside significant M&A developments (GameStop's unsolicited eBay bid, Northern Oil & Gas's Canadian entry, Cumberland's asset sale). Period-over-period trends show mixed earnings quality: CSW Industrials grew revenue 23% YoY but saw operating margin contract 500 bps, while AutoZone's same-store sales rose 4.1% but gross margin fell 57 bps. Insider activity is limited but notable—Delta extended its lock-up on Wheels Up, signaling confidence. Risk flags center on going concern issues (Veritone, Global Interactive, TransCode) and regulatory non-compliance (Nuvve, Specificity). Opportunities arise from FDA appeal wins (Outlook Therapeutics), clinical catalysts (Editas, Cartesian), and strategic expansions (NOG, Ryan Specialty buyback). Overall, the digest points to a bifurcated market where growth is often costly, and investors must differentiate between sustainable outperformance and leveraged expansion.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 26, 2026

The 50 filings reveal a mixed picture for the S&P 500 Consumer Discretionary sector. Key themes include margin compression (AutoZone, Modine), insider selling (Veradigm), and regulatory catalysts (American Woodmark, Boxabl). AutoZone's 8.4% revenue growth was offset by a 57 bps gross margin decline, while Modine reported record sales (+47% YoY) but saw GAAP earnings fall 34% due to a pension charge. Veradigm's long-delayed filings showed a 5% revenue decline and a swing to a $292M loss. On the positive side, American Woodmark cleared FTC hurdles for its merger with MasterBrand, and Boxabl received Texas regulatory approval ahead of its SPAC merger. Capital allocation trends show increased reliance on dilutive financing (Future FinTech) and debt issuance (PNC, Ares Strategic Income Fund). Insider activity was limited, but notable CEO promotions (Medifast) and director appointments (Palomar) signal confidence. Overall, the sector faces headwinds from cost inflation and tariffs, but select companies with strong execution and catalysts offer opportunities.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 26, 2026

The 35 filings from the S&P 500 Healthcare sector reveal a sector bifurcated between high-risk, cash-burning biotechs and stable, capital-returning companies. A dominant theme is aggressive capital raising via dilutive offerings (Editas, Assembly Biosciences) to fund clinical milestones, contrasted with shareholder return programs (Ryan Specialty's $300M buyback increase). Insider sentiment is mixed, with significant shareholder dissent on executive compensation at Thermo Fisher (68.2% against say-on-pay) and Spruce Biosciences (38% against), signaling governance concerns. The most critical development is Editas Medicine's dual filing: positive preclinical data for EDIT-401 (90% LDL-C reduction) is overshadowed by a $125M dilutive offering and liver toxicity signals at higher doses, creating a high-risk/high-reward binary catalyst. Portfolio-level trends show a focus on gene editing and rare disease, with several companies (Pacira, Editas) defending or advancing IP estates, while others like Specificity face restatements and accounting failures. The sector presents a clear dichotomy: invest in established players with strong capital allocation or speculate on binary clinical catalysts with significant dilution risk.

11 high priority 24 medium 35 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 26, 2026

This intelligence stream analyzes 10 DEF 14A filings, revealing a stark bifurcation in the US small-cap and SPAC landscape. A dominant theme is existential distress: 4 of the 10 companies (Veritone, Origin Materials, Klotho Neurosciences, and multiple SPACs) are facing going-concern risks, liquidation, or Nasdaq non-compliance, with a combined materiality score of 8-10/10. This contrasts sharply with the operational strength of AZZ Inc., which reported record sales and profitability, a 40%+ share price increase, and a 39th consecutive year of profitability. The SPAC sector remains under severe pressure, with Bowen, Mountain Lake, and Pantages all seeking last-minute deadline extensions to avoid liquidation, highlighting a systemic failure to consummate deals. Insider activity is notably absent in most filings, but the unanimous board recommendations for dissolution at Origin Materials and the high insider ownership (70.3%) at Bowen voting for an extension provide critical signals. Period-over-period comparisons from AZZ show strong debt reduction ($385.3M) and shareholder returns ($43M in dividends/buybacks), while the distressed companies show deteriorating equity structures via reverse splits and massive share increases. The most actionable insights revolve around the binary outcomes of SPAC liquidations, the value-destructive nature of reverse splits, and the relative safe-haven of established industrial performers like AZZ.

10 high priority 10 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 26, 2026

The IPO pipeline is active with 9 filings on May 26, 2026, spanning diverse sectors including specialty chemicals (VARSAL TECH), biotech (Kardigan, GeoVax), solar construction (SOLV Energy), power solutions (Forgent), SPAC (Crestone), quantum computing via SPAC merger (SeeQC), space/defense (Firefly Aerospace), and a UK-based company (DPC Holdings). A key theme is the prevalence of mixed sentiment, with most issuers showing significant financial challenges: widening net losses (Kardigan's Q1 2026 loss tripled YoY), declining government revenue (GeoVax's Q1 2026 contract revenue dropped to $0), and material weaknesses in internal controls (VARSAL TECH). Insider activity is notably absent across all filings, suggesting limited management conviction at current valuations. Capital allocation is focused on R&D and expansion, with no dividends or buybacks. The most critical development is SeeQC's SPAC merger with a $65M PIPE, but execution risk exists as only 48.8% of warrant holders have consented (needs 65%). Sector themes reveal a bifurcation: capital-intensive industrial IPOs (VARSAL, SOLV, Forgent) carry high debt and customer concentration, while biotech IPOs (Kardigan, GeoVax) show escalating cash burn with no product revenue. The absence of insider buying and prevalence of net losses suggest investors should be highly selective, focusing on companies with clear catalysts like GeoVax's Phase 3 trial or Firefly's NASA contract.

9 high priority 9 total filings
· daily

Global High-Priority Regulatory Events — May 26, 2026

This digest covers 50 filings from May 26, 2026, revealing a market bifurcated between aggressive capital deployment (M&A, IPOs, debt raises) and deep distress (bankruptcies, insolvencies, going-concern warnings). A dominant theme is the quantum technology sector, where Terra Quantum AG is simultaneously in play with two SPACs (Axiom Intelligence and Mountain Lake), though exclusivity has expired on one, creating deal uncertainty. The energy sector shows strategic expansion, with Northern Oil & Gas entering Canada via a $259M Duvernay Shale acquisition, while APA Corp faces notable shareholder dissent (14% against say-on-pay). Credit markets are active, with Ares Capital upsizing its facility to $5.48B and Encore Capital issuing $750M in notes, signaling strong institutional liquidity. On the distress side, Trinseo PLC filed for Chapter 11 to reduce debt by $2B, wiping out equity, while multiple Indian companies (Kallam Textiles, Quadrant Televentures, Tricom Fruit Products) remain in insolvency proceedings. Several companies, including Veritone and Global Interactive Technologies, received going-concern warnings from auditors. The IPO pipeline is robust with 5 new filings (Quantinuum, Applied Aerospace, INNIO, Varsal Tech, ERock), though many are controlled companies or have material weaknesses. Insider activity was limited, but the most significant signal is Ryan Cohen's public proposal to acquire eBay for $125/share via GameStop, a highly unconventional move. Overall, the data suggests a 'risk-on' environment for institutional capital and strategic buyers, but acute risk for equity holders in over-levered or cash-burning entities.

50 high priority 50 total filings